CN120478323A - 丙磺舒在治疗癫痫性疾病、病症或病况中的用途 - Google Patents

丙磺舒在治疗癫痫性疾病、病症或病况中的用途

Info

Publication number
CN120478323A
CN120478323A CN202510416283.6A CN202510416283A CN120478323A CN 120478323 A CN120478323 A CN 120478323A CN 202510416283 A CN202510416283 A CN 202510416283A CN 120478323 A CN120478323 A CN 120478323A
Authority
CN
China
Prior art keywords
probenecid
epilepsy
subject
day
seizures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510416283.6A
Other languages
English (en)
Chinese (zh)
Inventor
N·鲁阿什
E·多西
G·于贝菲尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Western Dais Paris, University of
Paris Foundation For Science And Literature
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Western Dais Paris, University of
Paris Foundation For Science And Literature
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Western Dais Paris, University of, Paris Foundation For Science And Literature, Centre National de la Recherche Scientifique CNRS, Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Sorbonne Universite, Commissariat a lEnergie Atomique et aux Energies Alternatives CEA filed Critical Western Dais Paris, University of
Publication of CN120478323A publication Critical patent/CN120478323A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202510416283.6A 2017-07-13 2018-07-13 丙磺舒在治疗癫痫性疾病、病症或病况中的用途 Pending CN120478323A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17305934.6A EP3427729A1 (en) 2017-07-13 2017-07-13 Probenecid for use in treating epileptic diseases, disorders or conditions
EP17305934.6 2017-07-13
PCT/EP2018/069092 WO2019012109A1 (en) 2017-07-13 2018-07-13 PROBENECID FOR USE IN THE TREATMENT OF EPILEPTIC DISEASES, DISORDERS OR DISORDERS
CN201880059798.3A CN111386107A (zh) 2017-07-13 2018-07-13 丙磺舒在治疗癫痫性疾病、病症或病况中的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880059798.3A Division CN111386107A (zh) 2017-07-13 2018-07-13 丙磺舒在治疗癫痫性疾病、病症或病况中的用途

Publications (1)

Publication Number Publication Date
CN120478323A true CN120478323A (zh) 2025-08-15

Family

ID=59384111

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880059798.3A Pending CN111386107A (zh) 2017-07-13 2018-07-13 丙磺舒在治疗癫痫性疾病、病症或病况中的用途
CN202510416283.6A Pending CN120478323A (zh) 2017-07-13 2018-07-13 丙磺舒在治疗癫痫性疾病、病症或病况中的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201880059798.3A Pending CN111386107A (zh) 2017-07-13 2018-07-13 丙磺舒在治疗癫痫性疾病、病症或病况中的用途

Country Status (6)

Country Link
US (2) US12318358B2 (enExample)
EP (2) EP3427729A1 (enExample)
JP (1) JP7369693B2 (enExample)
CN (2) CN111386107A (enExample)
CA (1) CA3070178A1 (enExample)
WO (1) WO2019012109A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021180857A1 (en) * 2020-03-11 2021-09-16 Iterum Therapeutics International Limited Combinations of beta-lactam compounds, probenecid, and valproic acid and uses thereof
TWI804037B (zh) * 2021-11-02 2023-06-01 長庚醫療財團法人高雄長庚紀念醫院 生酮飲食之評估系統及其運作方法
EP4505999A1 (en) 2023-08-07 2025-02-12 Panntherapi Probenecid formulations

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US902695A (en) 1907-12-31 1908-11-03 Stasia B Staley Package-tie.
JPS586027A (ja) 1981-07-01 1983-01-13 住友電気工業株式会社 高圧ケ−ブルの接続部
GB2104078B (en) 1981-08-14 1985-01-23 London Polytech New aminoacid isomers, their production and their medicinal use
NL8500847A (nl) 1984-03-29 1985-10-16 Sandoz Ag Gesubstitueerde alfa-aminozuren, hun bereiding en farmaceutische preparaten die ze bevatten.
CA1248531A (en) 1984-04-17 1989-01-10 Jeffrey C. Watkins 4-substituted piperazine-2-carboxylic acids
US4906621A (en) 1985-05-24 1990-03-06 Ciba-Geigy Corporation Certain 2-carboxypiperidyl-alkylene phosphonic acids and esters thereof useful for the treatment of disorders responsive to N-methyl-D-aspartate receptor blockade
US4746653A (en) 1986-02-28 1988-05-24 Ciba-Geigy Corporation Certain hetero phosphonic acid derivatives of 2-piperidine or 2-tetrahydropyridinecarboxylates and esters thereof which are useful for the treatment of disorders responsive to blockade of the NMDA receptor in mammals
US4657899A (en) 1986-04-09 1987-04-14 Nova Pharmaceutical Corporation Antagonists of specific excitatory amino acid neurotransmitter receptors
US4812458A (en) 1986-09-16 1989-03-14 A/S Ferrosan 6,7-disubstituted-2,3-dihydroxyquinoxaline compounds, pharmaceutical compositions thereof, and their use as neuroleptics
IE66149B1 (en) 1986-09-16 1995-12-13 Novo Nordisk As Quinoxaline compounds and their preparation and use
US4705781A (en) 1986-10-08 1987-11-10 Giba-Geigy Corporation Method of treating cerebral ischemia using 4-(phosphono substituted lower alkyl or lower alkenyl)piperazine-2-carboxylic acids and salts, esters and amides thereof
GB8625941D0 (en) 1986-10-30 1986-12-03 Sandoz Ltd Substituted alpha-amino acids
DE3768000D1 (de) 1986-11-21 1991-03-14 Ciba Geigy Ag Ungesaettigte phosphonsaeure und derivate.
GB8703749D0 (en) 1987-02-18 1987-03-25 Sandoz Ltd Piperazinecarboxylic acid
US4761405A (en) 1987-03-04 1988-08-02 Nova Pharmaceutical Corporation Antagonists of specific excitatory amino acid neurotransmitter receptors having increased potency
DK146787A (da) 1987-03-23 1988-09-24 Ferrosan Heterocykliske forbindelser, deres fremstilling og anvendelse
EP0302826A3 (de) 1987-08-04 1991-04-03 Ciba-Geigy Ag Verfahren zur Herstellung neuer ungesättigter Aminosäureverbindungen
GB8719102D0 (en) 1987-08-12 1987-09-16 Merck Sharp & Dohme Therapeutic agents
US4918064A (en) 1987-10-21 1990-04-17 G. D. Searle & Co. Phenyl glycines for use in reducing neurotoxic injury
NO179551C (no) 1987-11-10 1996-10-30 Novo Nordisk As Analogifremgangsmåte for fremstilling av terapeutisk virksomme kinoxalinforbindelser
GB8727792D0 (en) 1987-11-27 1987-12-31 Merck Sharp & Dohme Therapeutic agents
US4904681A (en) 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
US4968678A (en) 1988-02-19 1990-11-06 Eli Lilly And Company Tetrazole excitatory amino acid receptor antagonists
JPH0210544A (ja) 1988-06-29 1990-01-16 Canon Inc 光磁気記憶装置
ATE101117T1 (de) 1988-05-16 1994-02-15 Searle & Co 2-amino-4,5-methylenadipinsaeure-verbindungen fuer die behandlung von cns-erkrankungen.
DK160941C (da) 1988-06-28 1991-10-21 Novo Nordisk As Kondenserede 2,3-dihydroxypyraziner, fremgangsmaade til deres fremstilling og farmaceutiske praeparater, hvori forbindelserne indgaar
GB8823605D0 (en) 1988-10-07 1988-11-16 Merck Sharp & Dohme Therapeutic agents
CA2000901A1 (en) 1988-10-21 1990-04-21 Alexis A. Cordi Phosphono-hydroisoquinoline compounds useful in reducing neurotoxic injury
DK716188D0 (da) 1988-12-22 1988-12-22 Ferrosan As Quinoxalinforbindelser, deres fremstilling og anvendelse
DK715888D0 (da) 1988-12-22 1988-12-22 Ferrosan As Quinoxalinforbindelser, deres fremstilling og anvendelse
US5187171A (en) 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
US4902695A (en) 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
DE69029668T2 (de) 1989-03-08 1997-08-07 Merck Sharp & Dohme Tetrahydroquinolin-Derivate, verwendbar bei neurodegenerativen Krankheiten
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US4902687A (en) 1989-03-27 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
ATE112282T1 (de) 1989-04-07 1994-10-15 Ciba Geigy Ag Ungesättigte aminodicarbonsäurederivate.
GB8908529D0 (en) 1989-04-14 1989-06-01 Merck Sharp & Dohme Therapeutic agents
US4960786A (en) 1989-04-24 1990-10-02 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
PT93943A (pt) 1989-05-05 1991-02-08 Searle & Co Processo para a preparacao de composicoes contendo compostos indole-2-carboxilato para tratamento de perturbacoes do snc
CA2025326C (en) 1989-09-19 2001-04-24 Jeffrey P. Whitten Nmda antagonists
DE59009368D1 (de) 1989-09-26 1995-08-10 Ciba Geigy Ag Phosphonsäure, Verfahren zur Herstellung und Verwendung als Arzneimittelwirkstoff.
DE69201141T2 (de) * 1991-02-28 1995-05-11 Merrell Dow Pharma NMDA-Antagonisten.
WO1993004688A1 (en) * 1991-09-09 1993-03-18 Warner-Lambert Company Pharmaceutical preparation containing an uricosuric and an excitatory amino acid antagonist
US5318985A (en) 1991-12-20 1994-06-07 Merrell Dow Pharmaceuticals Inc. Potentiation of NMDA antagonists

Also Published As

Publication number Publication date
CA3070178A1 (en) 2019-01-17
JP7369693B2 (ja) 2023-10-26
RU2020106762A3 (enExample) 2021-11-10
WO2019012109A1 (en) 2019-01-17
US20200163916A1 (en) 2020-05-28
US12318358B2 (en) 2025-06-03
EP3427729A1 (en) 2019-01-16
RU2020106762A (ru) 2021-08-13
JP2020527172A (ja) 2020-09-03
US20250288544A1 (en) 2025-09-18
CN111386107A (zh) 2020-07-07
EP3651758A1 (en) 2020-05-20

Similar Documents

Publication Publication Date Title
US20250288544A1 (en) Probenecid for use in treating epileptic diseases, disorders or conditions
RU2499598C2 (ru) Способы лечения нарушений с применением селективного антагониста nr2b-подтипа nmda рецепторов
ES2769578T3 (es) Hidantoínas que modulan el procesamiento de APP mediado por BACE
JP7642735B2 (ja) アルツハイマー病を治療するための抗ａベータプロトフィブリル抗体及びベータ－セクレターゼｂａｃｅ１阻害剤を含む組成物
JP7519359B2 (ja) レシニフェラトキシンを投与することによってパーキンソン病を処置するための方法
KR20080055967A (ko) 섬유 근육통 증후군의 장기 치료를 위한 밀라시프란
US20240366566A1 (en) Use of carbamate compound for prevention, alleviation or treatment of status epilepticus
US20210128537A1 (en) T-type calcium channel modulators and methods of use thereof
CA2814828C (en) Method of treatment for mental disorders
JP7697110B2 (ja) 精神神経障害を処置するための組成物および方法
ES3004543T3 (en) Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
RU2785842C2 (ru) Применение пробенецида для лечения эпилептических заболеваний, нарушений и состояний
ES2446296T3 (es) Agente medicinal para el tratamiento de trastornos de la circulación cerebral o del flujo sanguíneo cerebral inducidos por beta amiloide
JPWO2021156769A5 (enExample)
JP5714572B2 (ja) 精神障害およびその症状の治療のためのｋｃｎｑカリウムチャネル活性の調節方法
ES2832549T3 (es) Composiciones y métodos para tratar la esclerosis lateral amiotrófica en respondedores
WO2025188951A1 (en) Fused amino pyrimidine compounds for treatment of seizure disorders
CN119384295A (zh) 以纹状体纹状小体的多巴胺d1信号为靶点的强迫性障碍的药物疗法
WO2025189166A1 (en) Pharmaceutical compounds for treatment of bipolar disorder
WO2025193971A1 (en) Methods of treating and reducing the likelihood of developing epilepsy
Pal et al. 38th Annual Meeting of the Society for Neuroscience in Anesthesiology and Critical Care, San Diego, California, October 15, 2010
JPWO2000007593A1 (ja) 難治性てんかんの治療薬又は予防薬
WO2014088106A1 (ja) 線維筋痛症の予防または治療薬

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination